Study identifier:315
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Double-blind, three-way crossover intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients
Barrett's esophagus
Phase 4
No
Esomeprazole Magnesium
All
50
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 40mg twice daily | - |
Experimental: 2 40mg three times daily | - |
Experimental: 3 20mg three times daily | - |